Advertisement
Advertisement
U.S. markets close in 5 hours 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Acumen Pharmaceuticals, Inc. (ABOS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.45+0.05 (+0.93%)
As of 09:52AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close5.40
Open5.41
Bid5.10 x 800
Ask5.59 x 800
Day's Range5.41 - 5.45
52 Week Range3.02 - 19.46
Volume966
Avg. Volume172,024
Market Cap220.732M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateMar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ABOS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Acumen Pharmaceuticals, Inc.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • GlobeNewswire

    Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

    CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update. To pa

  • GlobeNewswire

    Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease

    Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytical assaysCHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the study of soluble amyloid beta oligomers (AβOs), toxic proteins that accumulate early in Alzheimer’s disease (AD). This methodology will be presented in a poster at the Alzheimer’s Association Internat

  • GlobeNewswire

    Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

    CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences: The Alzheimer’s Association International Conference (AAIC), in San Diego and virtually, from Sunday, July 31, to Thursday, August 4, 2022 Acumen scientists will

Advertisement
Advertisement